|
Post by hellodolly on Dec 20, 2017 7:35:55 GMT -5
While the 'marketing guy' has had measures of success, as well as, by the your use of specific labels of CEO strengths, Mike C. therefore shouldn't be capable of being a 'finance guy'. Yet, he is perfectly capable of surrounding himself with the right financing guys to push MNKD across the goal line. Whereas, the "Finance Guy" had the wherewithal to conduct routine day-to-day CFO business (as the CEO), he didn't surround himself with any proven marketing guys. THAT is the difference from "then" and "now" my friend. But Dolly, didn't the finance CEO surrounded himself with the current marketing guy CEO? But yes, he did and as it would be...one trumped the other right of his job so fast, the 'finance guy' didn't do financing for long. Mike's ' time in grade' at MNKD was much less compared to Matt who was there much longer. But, you did bring up a valid point. Ever bring in talent to your organization that was so good that 'talent' took your job? There's a saying we used to tell our kids in HS baseball, (applicable to anything) - "Hard work beats talent when talent doesn't work hard." Is that what happened to Matt?
|
|
|
Post by babaoriley on Dec 20, 2017 7:51:04 GMT -5
Mike's a steamroller type. It didn't take him long to get rolling intra-company. What I hope he can do is steamroll some insurance companies. Not quite as easy as getting the top spot at MNKD.
|
|
|
Post by kc on Dec 20, 2017 11:40:55 GMT -5
You can bet that Mike is working the insurance market very hard. He knows the drill. It takes time. It takes Patients pushing for Afrezza and that will come with the social media effect from advertising and patient awareness. Old doctors don't like changes from the same old same old. They have been wined and dined by the big three cartel companies. We have little to offer the old doctors other than great outcomes for their patients using Afrezza.
|
|
|
Post by falconquest on Dec 20, 2017 19:29:17 GMT -5
While the 'marketing guy' has had measures of success, as well as, by the your use of specific labels of CEO strengths, Mike C. therefore shouldn't be capable of being a 'finance guy'. Yet, he is perfectly capable of surrounding himself with the right financing guys to push MNKD across the goal line. Whereas, the "Finance Guy" had the wherewithal to conduct routine day-to-day CFO business (as the CEO), he didn't surround himself with any proven marketing guys. THAT is the difference from "then" and "now" my friend. But Dolly, didn't the finance CEO surrounded himself with the current marketing guy CEO? Bingo! And once that marketing guy proves himself to me I'll be an advocate. So far? the jury is still out for me.
|
|
|
Post by falconquest on Dec 20, 2017 19:34:04 GMT -5
Here is what I believe in a nutshell. I believe that Al Mann thought that people would flock to Afrezza because they could avoid needles and because it is a much better insulin. I also believe that he thought he could create a myriad of products based on the Technosphere delivery system (embarrassment of riches anyone?) Chris Viehbacher bought into that story but was dumped by Sanofi and along came Olivier Brandicourt who didn't buy it at all. He dropped Mannkind like a hot potato. We moved out our finance based CEO for a marketing CEO with the notion of going it alone and this is where we are today. Unfortunately the marketing guy hasn't been able to move needle much on sales despite the "in-house" sales force. We are treading water at best. Good luck to all. “...and this is where WE are today” So after having sold all of your shares a while back you recently jumped back in sometime after this last stock offering? Wrong. But if the stock price continues this slide I'll get back in. Maybe I can ride another manipulated rise. It will be nice to make a profit in Mannkind for a change.
|
|
|
Post by mnholdem on Dec 21, 2017 12:40:34 GMT -5
Just curious how many here have considered yourself OCD challenged. For those of us here every day I'd think there are quite a few of us. There's hope for you buddy. Biohaven Pharma just enrolled its first patient in it's phase 2/3 clinical trial of Trigriluzole for patients with Obsessive-Compulsive Disorder. It may not be too late to get in on this.
|
|
|
Post by thekindaguyiyam on Dec 21, 2017 12:51:08 GMT -5
Just curious how many here have considered yourself OCD challenged. For those of us here every day I'd think there are quite a few of us. There's hope for you buddy. Biohaven Pharma just enrolled its first patient in it's phase 2/3 clinical trial of Trigriluzole for patients with Obsessive-Compulsive Disorder. It may not be too late to get in on this.
LOL. Hey. I looked at my bank account yesterday. I went to Fidelity and considered transferring funds for more shares and Didn't. Today I ask myself "why". You don't have to buy Mannkind Stock to be OCD. To qualify you may simply be posting here everyday buddy! :-) an after thought: what a great market targeting group the OCD community is for the OCD drug whose patients "have the compulsion to have this new drug prescribed".
|
|
|
Post by mnholdem on Dec 21, 2017 14:49:20 GMT -5
Maybe you should talk Castagna into developing an OCD-Technosphere drug. MannKind would have plenty of trial patients applications just from this forum.
|
|
|
Post by thekindaguyiyam on Dec 21, 2017 15:28:52 GMT -5
Maybe you should talk Castagna into developing an OCD-Technosphere drug. MannKind would have plenty of trial patients applications just from this forum. I've been thinking the same thing since you brought it up. So I guess with the feedback here I'm not on an Island. What some would call OCD others would call DD. Like most things it's just a matter of perception. Yesterday was not an easy day for long shareholders; it wasn't easy for me even though I practiced some detachment. Today the sun shines.
|
|
|
Post by kc on Dec 22, 2017 14:56:20 GMT -5
Temptation almost got me today. I have been on the 10 step program for years with MannKind. Temptation just got the best of me. 10 Step program failed. But hopefully MannKind will not let me fail.
|
|
|
Post by thekindaguyiyam on Dec 22, 2017 15:57:33 GMT -5
Oops. In @ 2.45. I guess my 12 steps starts again Tuesday.
|
|
|
Post by alethea on Dec 22, 2017 16:06:21 GMT -5
Oops. In @ 2.45. I guess my 12 steps starts again Tuesday. Good for you. Today was textbook manipulation. Without the Wall Street crooks the trading volume would be at most a couple hundred thousand shares. They cannot keep it up forever IF, that's IF, Sales keep rising at the recent pace. January 15 or 18, the deadline for Dearfield to purchase 4 million more shares at a minimum of $3.25 will shed more light on things. I expect the crooks to be working very, very had for the month or so.
|
|
|
Post by mnholdem on Dec 22, 2017 18:53:22 GMT -5
Just remember that, when the time comes, Goldman Sucks, their affiliates and many of the big Wall Street investment firms will be just as eager to make $billion driving this up, up, up. Up or down, they seldom lose...if ever!
|
|
|
Post by kc on Dec 22, 2017 19:07:46 GMT -5
Oops. In @ 2.45. I guess my 12 steps starts again Tuesday. Same buy in cost
|
|
|
Post by thekindaguyiyam on Apr 11, 2018 11:11:40 GMT -5
"forgive me father for I have sinned". Gotta restart the program as I bought more today (for the last time Again). Had to. Was about to blow a gasket. relatively small purchase @ 1.65. wish me luck with the "strength" to keep my Benny's in the Bank.
|
|